Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Company Overview

Syros Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression. Founded in 2015 as a spin-out from the Broad Institute, Syros leverages its proprietary gene control platform to identify and drug key noncoding regions of the genome that regulate disease-driving genes. The company’s approach aims to convert previously undruggable gene targets into precise medicines for patients with cancer and rare genetic disorders.

Syros’ lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) characterized by RARA dependence. In addition, Syros is advancing SY-1365, a selective CDK7 inhibitor, through early-stage studies in solid tumors and hematologic malignancies. Beyond oncology, the company has preclinical programs in rare genetic diseases, including SY-2101, an investigational therapy for Gaucher disease.

Utilizing a research site in Cambridge and collaborations with academic and industry partners, Syros aims to accelerate its pipeline by integrating genomics, chemical biology and translational science. The company emphasizes a disciplined clinical strategy, selecting patient populations based on molecular biomarkers to maximize the potential for clinical benefit. Syros Pharmaceuticals is publicly traded on the NASDAQ under the symbol SYRS and continues to build a diversified portfolio of gene control–based medicines.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 5,467 shs
• Average Volume: 16,862 shs
• Market Capitalization: $2.68 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 10/31/2024
• Today: 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYRS
• CIK: 1556263
• Web: www.syros.com
• Phone: (617) 744-1340
• Fax: N/A
• Employees: 120
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$164.57 million
• Net Margins: N/A
• Pretax Margin: -25,275.20%
• Return on Equity: -3,369.56%
• Return on Assets: -97.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $386 thousand
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 26,832,000
• Free Float: 23,542,000
• Market Cap: $2.68 thousand
• Optionable: No Data
• Beta: 1.31